CTLA4 and melanoma: Currently, three immune checkpoint inhibitors (ICIs) are approved for the treatment of stage IV melanoma: the anti-CTLA4 antibody ipilimumab, and the anti-PD1 antibodies nivolumab and pembrolizumab [1,5,6].